OMEGA-3-PENTAENOIC ACIDS

Summary

Omega-3-Pentaenoic Acids (CHEMBL4650221) is a phase-3 clinical-stage small molecule; indicated across 1 condition including hypertriglyceridemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 949.4 Da · C63H96O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650221
Name	OMEGA-3-PENTAENOIC ACIDS
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	156009449
Molecular formula	C63H96O6
Molecular weight	949.4
InChIKey	MSHVEAAKYBMOTM-VVUKEZRKSA-N

SMILES: CC/C=C/C/C=C/C/C=C/C/C=C/C/C=C/CCCCCC(=O)O.CC/C=C/C/C=C/C/C=C/C/C=C/C/C=C/CCCCC(=O)O.CC/C=C/C/C=C/C/C=C/C/C=C/C/C=C/CCCC(=O)O

IUPAC name: (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoic acid;(6E,9E,12E,15E,18E)-henicosa-6,9,12,15,18-pentaenoic acid;(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoic acid

Also known as: MAT-9001, MAT9001

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hypertriglyceridemia	3	MONDO:0005347	EFO:0004211

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04662528	PHASE3	WITHDRAWN	Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).